Related Experiment Video

Updated: May 6, 2026

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays
07:42

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Published on: September 19, 2018

7.1K

Tyrosine kinase gene rearrangements in epithelial malignancies

Alice T Shaw1, Peggy P Hsu, Mark M Awad

  • 1Massachusetts General Hospital Cancer Center, Boston, Massachusetts 02114, USA.

Nature Reviews. Cancer
|October 18, 2013
PubMed

Insights

Chromosomal rearrangements activate oncogenic kinases like ALK, ROS1, and RET in epithelial cancers. Targeted therapies show promise, validating these fusion kinases as key targets for cancer treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Chromosomal rearrangements frequently activate oncogenic kinases in epithelial cancers.
  • Activated fusion kinases drive cancer initiation, progression, and are often druggable targets.

Purpose of the Study:

  • To review the etiology, pathogenesis, and clinical features of cancers with oncogenic fusion kinases.
  • To discuss clinical outcomes of targeted therapies for anaplastic lymphoma kinase (ALK), ROS1, and RET.
  • To explore strategies for identifying new fusion kinases in solid tumors.

Main Methods:

  • Literature review of existing studies on oncogenic fusion kinases.
  • Analysis of clinical data regarding targeted therapy responses.
  • Exploration of methods for novel kinase target discovery.

Main Results:

  • Fusion kinases such as ALK, ROS1, and RET are critical drivers in various epithelial cancers.
  • Small-molecule inhibitors targeting these kinases demonstrate significant clinical efficacy.
  • Targeted therapies offer a validated approach for treating cancers with specific kinase fusions.

Conclusions:

  • Oncogenic fusion kinases are important therapeutic targets in epithelial cancers.
  • Understanding the clinical features and outcomes associated with these kinases is crucial for treatment.
  • Continued research is needed to discover and target additional fusion kinases in solid tumors.

More Related Videos

Oncogenic Gene Fusion Detection Using Anchored Multiplex Polymerase Chain Reaction Followed by Next Generation Sequencing09:49

Oncogenic Gene Fusion Detection Using Anchored Multiplex Polymerase Chain Reaction Followed by Next Generation Sequencing

Published on: July 5, 2019

9.1K
Induction and Analysis of Epithelial to Mesenchymal Transition10:37

Induction and Analysis of Epithelial to Mesenchymal Transition

Published on: August 27, 2013

38.0K

Related Concept Videos

Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
15.7K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.6K
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
5.7K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
3.7K
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

2.2K